Ena/VASP-EVH1 inhibition prevents chemotaxis and metastasis by blocking the EVH1-WAVE2 interaction

Area of Science:

• Cell Biology
• Cancer Research
• Pharmacology

Background:

• Cancer metastasis, the spread of cancer cells, is a major cause of cancer-related deaths.
• Cancer cell motility, driven by actin dynamics in lamellipodia, is crucial for metastasis.
• Ena/VASP proteins and the WAVE regulatory complex are key regulators of actin polymerization and cell migration.

Purpose of the Study:

• To investigate the cross-talk between Ena/VASP proteins and WAVE2 in cancer cell extravasation.
• To evaluate the therapeutic potential of targeting the Ena/VASP-WAVE2 interaction for inhibiting cancer metastasis.

Main Methods:

• Utilized genetic manipulation of WAVE2, including mutating the EVH1 domain recognition motif.
• Assessed cancer cell chemotaxis and extravasation using triple-negative MDA-MB-231 breast cancer cells.
• Employed zebrafish and mouse models for in vivo metastasis and extravasation studies.
• Administered an Ena/VASP-EVH1 inhibitor in preclinical metastasis models.

Main Results:

• WAVE2 motif mutation abrogated chemotaxis and reduced extravasation of MDA-MB-231 cells in zebrafish.
• Orthotopic implantation of mutated cells in mice reduced macrometastasis and prolonged survival.
• Inhibition of Ena/VASP-EVH1 interaction significantly reduced in vivo metastasis.
• Demonstrated a critical role for Ena/VASP-WAVE2 interaction in cancer cell metastasis.

Conclusions:

• The Ena/VASP-WAVE2 interaction is essential for cancer cell migration and extravasation.
• Pharmacological targeting of this interaction presents a promising therapeutic strategy to reduce cancer metastasis.
• Interfering with Ena/VASP-WAVE2 may offer a novel approach to enhance cancer therapy outcomes.